Improving AAV vector manufacture: a question of scale

Published: 29 April 2021
Podcast
Silke Wissing,
Silke Wissing
Chief Scientific Officer, Cevec Pharmaceuticals
Dr Silke Wissing has wide-ranging experience in the fields of virology, cell biology and cell line development, as well as molecular biology. Before joining CEVEC in 2011, she held a position as a group leader in the Gladstone Institute for Virology and Immunology, San Francisco, where she performed research in the field of HIV-1 biology, stem cell research and cell line development. Dr. Silke Wissing holds a PhD in Biochemistry from the University of Tübingen.
Juliana Coronel,
Juliana Coronel
Head of Upstream Process Development, Cevec Pharmaceuticals
Jens Wölfel,
Jens Wölfel
Head of DSP and Analytics at CEVEC Pharmaceuticals
David Mainwaring,
David Mainwaring
at Pall
Amar Joshi
Amar Joshi
at Pall Biotech

Silke Wissing

Chief Scientific Officer, Cevec Pharmaceuticals

Juliana Coronel

Head of Upstream Process Development, Cevec Pharmaceuticals

Jans Wölfel

Head of Downstream Processing and Analytics, Cevec Pharmaceuticals

David Mainwaring

Principal Scientist, Pall

Amar Josh

Senior Scientist, Pall



Listen to the full podcast:



Listen to each individual question and answer:















This article is part of the Viral vector bioprocessing spotlight

Please note all fields marked with an * are mandatory

submit

Already registered? Login

If you have any problem accessing our content, please email info@insights.bio